Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats.
A study of the metabolic fate of [14C]SM-1652 after intravenous or intramuscular injection into rats showed that: (i) the elimination of the labeled compound from the blood was the same after intravenous and intramuscular injections; (ii) the radiolabeled drug was distributed rapidly and widely after intravenous administration with the highest concentration in the kidney and the lowest in the brain; (iii) placental transmission was slight, as it was passed into the milk, where the concentration was about 14% that of plasma; (iv) 33 and 67% of the administered radioactivity was excreted in urine and feces, respectively; (v) radioactivity in both urine and bile was ascribable to unaltered SM-1652; and (vi) upon repeated intramuscular injections twice daily, levels of labeled SM-1652 in tissue increased gradually, reaching a plateau at the 11th injection.
D000818:Animals; D001345:Autoradiography; D001646:Bile / Q000032:analysis; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism; D005243:Feces / Q000032:analysis; D005260:Female; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008892:Milk / Q000032:analysis; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014018:Tissue Distribution
D002511:Cephalosporins; C036666:cefpiramide